摘要:
Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.
摘要:
Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.
摘要:
The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific for binding to complement receptor (CR2) site on B lymphocytes linked to a target antigen. As shown in FIG. SA-SD immune complexes bound to monkey B cells are removed in concert with loss of CR2. FIGS. SA and SB demonstrate the % A1488 HB135 and % APhCy CD21 positive cells, out of the doubly positive FE CD20/PerCF CD45 population over time, after injection of A1488 labeled HB135 (an anti-CR2 antibody, administration indicated by first arrow) followed by injection of rabbit anti-mouse IgG (administration indicated by the second arrow). FIGS. SC and SD are plots of the molecules of equivalent soluble fluorochome (MESF) values for these populations.
摘要:
Constructs consisting of antigen-based heteropolymers (AHP's) are provided. The antigen-based heteropolymers comprise at least one monoclonal antibody specific for binding to complement receptor (CR1) site on a human or non-human primate erythrocyte, and the anti-CR1 monoclonal antibody is crosslinked to an antigen specific for a target pathogenic autoantibody. Further provided is a method for treating autoimmune diseases in human or non-human primates using the AHP.
摘要:
The present invention is directed to a process for the production of optionally cellular, polyurethane elastomer molding by reacting a reaction mixture containing(I) a polyisocyanate,(II) an isocyanate-reactive polymer having a molecular weight of about 1800 to 12,000,(III) about 5 to 50% by weight, based on the weight of component (II) of a chain extender comprising a sterically hindered aromatic diamine and(IV) an internal mold release agent mixture comprising(a) about 0.5 to 10% by weight, based on the weight of components (II) and (III) of a zinc carboxylate containing 8 to 24 carbon atoms per carboxylate group and(b) a compatibilizer comprising a member selected from the group consisting of nitrogen-containing, isocyanate-reactive, acyclic compounds and nitrogen-containing, isocyanate-reactive polymers in an amount sufficient to solubilize the zinc carboxylate so that when the internal mold release agent mixture is in admixture with components (II) and (III), the zinc carboxylate possesses improved resistance to precipitation,the reaction mixture being processed as a one-shot system by the RIM process at an isocyanate index of about 70 to 130.
摘要:
A hydrophobic polyurethane elastomer is disclosed comprising an isocyanate terminated prepolymer having an isocyanate content ranging from 4 to 12 wt. % NCO comprising the reaction product of: i) an OH terminated homopolymer of butadiene having molecular weight ranging from 1000 to 4000 and an OH functionality of from 1.9 to 2.1; ii) an aliphatic or cycloaliphatic diisocyanate; and a diol chain extender having a molecular weight ranging from 62 to 400.
摘要:
A di-hydroxy-functionalized linear non-crosslinked polyolefin is disclosed having no pendant chain-branched groups which is prepared by reacting 1,4-diacetoxy-2-butene with 1,5-cyclooctadiene in the presence of a catalyst comprising a ruthenium metal carbene complex, characterized in that the functionality number of said polyolefin as determined by NMR is 2.0 and the viscosity of said polyolefin ranges from about 800 to 16000 mPa.s @25.degree. C. at a number average molecular weight ranging from 2,600 to 6,500 g/mole. A prepolymer comprising the reaction of a polyisocyanate with the polyolefin is also disclosed.
摘要:
The present invention is directed to a process for the production of polyurethane elastomer moldings by reacting a reaction mixture in a closed mold, wherein said reaction mixture comprises:(a) an organic polyisocyanate;(b) an organic active hydrogen group-containing compound having a molecular weight of from 1800 to 12,000 and containing at least two active hydrogen groups;(c) 1,3,5-triethyl-2,6-diamino benzene and, optionally(d) a catalyst for the reaction between hydroxyl groups and isocyanate groups,wherein component (c) is present in an amount of from 25 to 35 percent by weight based on the combined weight of components (b) and (c), wherein the amounts of components (a), (b) and (c) are such that the isocyanate index of the reaction mixture is from about 90 to 110, and wherein all of said components are processed via a one-shot process whereby (a) is mixed simultaneously either with (b), (c) and (d) or with a non-reacted premixture of some or all of (b), (c) and (d).
摘要:
Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
摘要:
Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.